Literature DB >> 22751090

In vivo reprogramming for heart disease.

Huansheng Xu1, B Alexander Yi, Kenneth R Chien.   

Abstract

The term "lineage reprogramming" is typically used to describe the conversion of one differentiated somatic cell type into another without transit through a pluripotent intermediate. Two recent reports in Nature demonstrate that such a conversion can be achieved in the heart in situ, and suggest a novel, regenerative approach for the development of cardiac therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751090      PMCID: PMC3494388          DOI: 10.1038/cr.2012.101

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  15 in total

Review 1.  Towards regenerative therapy for cardiac disease.

Authors:  Leon M Ptaszek; Moussa Mansour; Jeremy N Ruskin; Kenneth R Chien
Journal:  Lancet       Date:  2012-03-10       Impact factor: 79.321

2.  MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes.

Authors:  Tilanthi M Jayawardena; Bakytbek Egemnazarov; Elizabeth A Finch; Lunan Zhang; J Alan Payne; Kumar Pandya; Zhiping Zhang; Paul Rosenberg; Maria Mirotsou; Victor J Dzau
Journal:  Circ Res       Date:  2012-04-26       Impact factor: 17.367

3.  Preventing and exploiting the oncogenic potential of integrating gene vectors.

Authors:  Ute Modlich; Christopher Baum
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

Review 4.  Extreme makeover: converting one cell into another.

Authors:  Qiao Zhou; Douglas A Melton
Journal:  Cell Stem Cell       Date:  2008-10-09       Impact factor: 24.633

5.  A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells.

Authors:  Stephanie Protze; Shahryar Khattak; Claire Poulet; Dirk Lindemann; Elly M Tanaka; Ursula Ravens
Journal:  J Mol Cell Cardiol       Date:  2012-04-28       Impact factor: 5.000

6.  Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size.

Authors:  Linda W van Laake; Robert Passier; Krista den Ouden; Chantal Schreurs; Jantine Monshouwer-Kloots; Dorien Ward-van Oostwaard; Cees J van Echteld; Pieter A Doevendans; Christine L Mummery
Journal:  Stem Cell Res       Date:  2009-06-02       Impact factor: 2.020

7.  Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.

Authors:  Masaki Ieda; Ji-Dong Fu; Paul Delgado-Olguin; Vasanth Vedantham; Yohei Hayashi; Benoit G Bruneau; Deepak Srivastava
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

8.  Generation of functional ventricular heart muscle from mouse ventricular progenitor cells.

Authors:  Ibrahim J Domian; Murali Chiravuri; Peter van der Meer; Adam W Feinberg; Xi Shi; Ying Shao; Sean M Wu; Kevin Kit Parker; Kenneth R Chien
Journal:  Science       Date:  2009-10-16       Impact factor: 47.728

9.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

10.  Heart repair by reprogramming non-myocytes with cardiac transcription factors.

Authors:  Kunhua Song; Young-Jae Nam; Xiang Luo; Xiaoxia Qi; Wei Tan; Guo N Huang; Asha Acharya; Christopher L Smith; Michelle D Tallquist; Eric G Neilson; Joseph A Hill; Rhonda Bassel-Duby; Eric N Olson
Journal:  Nature       Date:  2012-05-13       Impact factor: 49.962

View more
  1 in total

Review 1.  Regulation of Cardiac Cell Fate by microRNAs: Implications for Heart Regeneration.

Authors:  Margarida Gama-Carvalho; Jorge Andrade; Luis Brás-Rosário
Journal:  Cells       Date:  2014-10-29       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.